Jack Higgins Biography and Net Worth

Insider of Immunome

Dr. Jack Higgins is a biotechnology leader with over a decade of experience. He previously spent 11 years at Molecular Templates, Inc., serving in roles of increasing responsibility before being appointed Chief Development Sciences Officer. During his time at Molecular Templates, Dr. Higgins led discovery and development efforts for multiple clinical candidates and co-invented the company’s Engineered Toxin Body (ETB) platform. Dr. Higgins completed a fellowship in tumorimmunology at the National Cancer Institute. He holds a Ph.D. and M.S from the University of Arkansas and a B.S.from Texas A&M University.

What is Jack Higgins' net worth?: The estimated net worth of Jack Higgins is at least $126,848.00 as of August 15th, 2024. Higgins owns 16,000 shares of Immunome stock worth more than $126,848 as of May 15th. This net worth estimate does not reflect any other investments that Higgins may own. Additionally, Higgins receives an annual salary of $956,340.00 as Insider at Immunome. Learn More about Jack Higgins' net worth.
How old is Jack Higgins?: Higgins is currently 44 years old. There are 2 older executives and no younger executives at Immunome. The oldest executive at Immunome is Dr. Clay B. Siegall Ph.D., President, CEO & Chairman, who is 63 years old. Learn More on Jack Higgins' age.
What is Jack Higgins' salary?: As the Insider of Immunome, Inc., Higgins earns $956,340.00 per year. The highest earning executive at Immunome is Dr. Clay B. Siegall Ph.D., President, CEO & Chairman, who commands a salary of $1,430,000.00 per year. Learn More on Jack Higgins' salary.
How do I contact Jack Higgins?: The corporate mailing address for Higgins and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at investors@immunome.com. Learn More on Jack Higgins' contact information.
Has Jack Higgins been buying or selling shares of Immunome?: Jack Higgins has not been actively trading shares of Immunome over the course of the past ninety days. Most recently, Jack Higgins sold 3,524 shares of the business's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a transaction totalling $49,089.32. Following the completion of the sale, the insider now directly owns 16,000 shares of the company's stock, valued at $222,880. Learn More on Jack Higgins' trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 418,262 shares worth more than $3,425,760.18. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 17,904 shares worth more than $279,313.12. The most recent insider tranaction occured on March, 26th when CEO Clay B Siegall bought 137,100 shares worth more than $999,459.00. Insiders at Immunome own 8.6% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/26/2025.

Jack Higgins Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/15/2024	Sell	3,524	$13.93	$49,089.32	16,000

Jack Higgins Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $7.93

$7.62

$8.09

50 Day Range

MA: $7.68

$5.56

$9.21

2 Week Range

Now: $7.93

$5.15

$16.81

Volume

601,001 shs

Average Volume

916,618 shs

Market Capitalization

$689.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Jack Higgins Biography and Net Worth

What is Jack Higgins' net worth?

How old is Jack Higgins?

What is Jack Higgins' salary?

How do I contact Jack Higgins?

Has Jack Higgins been buying or selling shares of Immunome?

Who are Immunome's active insiders?

Are insiders buying or selling shares of Immunome?